| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 37 | 2024 | 964 | 5.690 |
Why?
|
| Health Care Costs | 34 | 2024 | 699 | 5.140 |
Why?
|
| Medicare | 41 | 2024 | 926 | 4.910 |
Why?
|
| Health Expenditures | 18 | 2023 | 202 | 3.810 |
Why?
|
| Early Detection of Cancer | 20 | 2023 | 1340 | 3.780 |
Why?
|
| Neoplasms | 58 | 2024 | 15927 | 3.710 |
Why?
|
| Medicare Part D | 9 | 2022 | 30 | 3.190 |
Why?
|
| Drug Costs | 9 | 2021 | 140 | 2.920 |
Why?
|
| Cost of Illness | 15 | 2024 | 505 | 2.560 |
Why?
|
| United States | 102 | 2024 | 15861 | 2.450 |
Why?
|
| Insurance, Health | 11 | 2024 | 261 | 2.440 |
Why?
|
| Breast Neoplasms | 39 | 2024 | 16215 | 2.440 |
Why?
|
| Hydrocarbons, Brominated | 4 | 2022 | 13 | 2.370 |
Why?
|
| Medication Therapy Management | 8 | 2024 | 35 | 2.220 |
Why?
|
| SEER Program | 26 | 2021 | 1047 | 2.130 |
Why?
|
| Delivery of Health Care | 13 | 2023 | 855 | 1.970 |
Why?
|
| Cancer Survivors | 7 | 2024 | 742 | 1.810 |
Why?
|
| Insurance Coverage | 11 | 2024 | 275 | 1.720 |
Why?
|
| Malignant Carcinoid Syndrome | 5 | 2021 | 40 | 1.670 |
Why?
|
| Flame Retardants | 3 | 2021 | 5 | 1.660 |
Why?
|
| Humans | 234 | 2024 | 270740 | 1.610 |
Why?
|
| Quality-Adjusted Life Years | 11 | 2021 | 236 | 1.590 |
Why?
|
| Quality of Health Care | 7 | 2019 | 618 | 1.450 |
Why?
|
| Mammography | 7 | 2024 | 1052 | 1.410 |
Why?
|
| Communication | 4 | 2024 | 839 | 1.390 |
Why?
|
| Mass Screening | 12 | 2022 | 1552 | 1.380 |
Why?
|
| Prostatic Neoplasms | 13 | 2023 | 5866 | 1.320 |
Why?
|
| Medical Oncology | 7 | 2023 | 1465 | 1.280 |
Why?
|
| Antineoplastic Agents | 15 | 2022 | 14617 | 1.250 |
Why?
|
| Health Services Accessibility | 8 | 2024 | 831 | 1.220 |
Why?
|
| Aged | 101 | 2024 | 73333 | 1.210 |
Why?
|
| Medication Adherence | 3 | 2023 | 513 | 1.180 |
Why?
|
| Smoking Cessation | 10 | 2024 | 776 | 1.170 |
Why?
|
| Female | 140 | 2024 | 148940 | 1.170 |
Why?
|
| Neuroendocrine Tumors | 7 | 2019 | 656 | 1.130 |
Why?
|
| Lung Neoplasms | 12 | 2023 | 12033 | 1.110 |
Why?
|
| Male | 117 | 2024 | 128315 | 1.040 |
Why?
|
| Taiwan | 9 | 2021 | 99 | 1.020 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2019 | 600 | 1.000 |
Why?
|
| Policy | 2 | 2023 | 52 | 0.990 |
Why?
|
| Logistic Models | 20 | 2024 | 3444 | 0.990 |
Why?
|
| Healthcare Disparities | 9 | 2023 | 657 | 0.980 |
Why?
|
| Epilepsy | 5 | 2020 | 931 | 0.980 |
Why?
|
| Neurosurgical Procedures | 6 | 2020 | 633 | 0.960 |
Why?
|
| Models, Economic | 7 | 2018 | 102 | 0.950 |
Why?
|
| Middle Aged | 82 | 2024 | 90352 | 0.930 |
Why?
|
| Prostatectomy | 8 | 2020 | 1003 | 0.930 |
Why?
|
| Physicians | 6 | 2023 | 854 | 0.920 |
Why?
|
| Colorectal Neoplasms | 8 | 2022 | 3707 | 0.910 |
Why?
|
| Prescription Drugs | 2 | 2023 | 61 | 0.890 |
Why?
|
| Biodegradation, Environmental | 2 | 2021 | 24 | 0.890 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2019 | 2386 | 0.870 |
Why?
|
| Medicare Part C | 1 | 2023 | 34 | 0.870 |
Why?
|
| Drugs, Generic | 4 | 2019 | 35 | 0.860 |
Why?
|
| Mastectomy, Segmental | 8 | 2017 | 1049 | 0.860 |
Why?
|
| Postoperative Complications | 9 | 2020 | 5681 | 0.840 |
Why?
|
| Costs and Cost Analysis | 12 | 2023 | 310 | 0.800 |
Why?
|
| Malformations of Cortical Development | 2 | 2020 | 59 | 0.800 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2019 | 2635 | 0.790 |
Why?
|
| Periodicals as Topic | 3 | 2023 | 317 | 0.760 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2022 | 7783 | 0.750 |
Why?
|
| Drug Dosage Calculations | 1 | 2021 | 45 | 0.750 |
Why?
|
| Breast Density | 1 | 2021 | 20 | 0.740 |
Why?
|
| Survivorship | 1 | 2021 | 116 | 0.740 |
Why?
|
| Hospitals | 2 | 2017 | 484 | 0.740 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2020 | 25 | 0.730 |
Why?
|
| Managed Care Programs | 3 | 2011 | 83 | 0.730 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2021 | 67 | 0.730 |
Why?
|
| Commerce | 2 | 2018 | 59 | 0.720 |
Why?
|
| Adult | 63 | 2024 | 82040 | 0.720 |
Why?
|
| Neuroma, Acoustic | 3 | 2014 | 58 | 0.720 |
Why?
|
| Health Policy | 4 | 2019 | 278 | 0.710 |
Why?
|
| Rhodopseudomonas | 1 | 2019 | 2 | 0.700 |
Why?
|
| Lymphedema | 3 | 2014 | 239 | 0.700 |
Why?
|
| Financing, Personal | 1 | 2019 | 13 | 0.690 |
Why?
|
| Epilepsy, Temporal Lobe | 5 | 2015 | 109 | 0.670 |
Why?
|
| Epilepsies, Partial | 1 | 2020 | 110 | 0.660 |
Why?
|
| Eligibility Determination | 5 | 2019 | 85 | 0.660 |
Why?
|
| Health Services Research | 3 | 2019 | 237 | 0.650 |
Why?
|
| Drug Resistant Epilepsy | 2 | 2020 | 217 | 0.650 |
Why?
|
| Aged, 80 and over | 37 | 2024 | 30998 | 0.650 |
Why?
|
| Health Status | 7 | 2023 | 631 | 0.640 |
Why?
|
| Databases, Factual | 11 | 2020 | 2250 | 0.640 |
Why?
|
| Insurance Claim Review | 6 | 2018 | 73 | 0.640 |
Why?
|
| Bronchoscopy | 2 | 2019 | 481 | 0.630 |
Why?
|
| Gyrus Cinguli | 1 | 2020 | 127 | 0.630 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2021 | 1302 | 0.630 |
Why?
|
| Intracranial Aneurysm | 3 | 2015 | 130 | 0.620 |
Why?
|
| Models, Statistical | 3 | 2024 | 1184 | 0.610 |
Why?
|
| Seizures | 3 | 2020 | 1001 | 0.610 |
Why?
|
| Microbiota | 2 | 2022 | 547 | 0.590 |
Why?
|
| Mandatory Programs | 1 | 2017 | 6 | 0.590 |
Why?
|
| Economics, Hospital | 1 | 2017 | 11 | 0.580 |
Why?
|
| Physician-Patient Relations | 4 | 2019 | 736 | 0.580 |
Why?
|
| Radiosurgery | 7 | 2020 | 1383 | 0.580 |
Why?
|
| Prescription Fees | 1 | 2017 | 17 | 0.580 |
Why?
|
| Off-Label Use | 1 | 2017 | 48 | 0.580 |
Why?
|
| Health Status Disparities | 4 | 2023 | 318 | 0.570 |
Why?
|
| Health Services Misuse | 2 | 2019 | 41 | 0.570 |
Why?
|
| Practice Guidelines as Topic | 7 | 2018 | 2400 | 0.570 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 354 | 0.570 |
Why?
|
| Ownership | 1 | 2017 | 40 | 0.570 |
Why?
|
| Administration, Oral | 5 | 2023 | 1608 | 0.550 |
Why?
|
| Telemedicine | 1 | 2023 | 552 | 0.550 |
Why?
|
| Kidney Neoplasms | 3 | 2019 | 3108 | 0.540 |
Why?
|
| Body Weight | 1 | 2021 | 1307 | 0.540 |
Why?
|
| Mastectomy | 7 | 2024 | 1553 | 0.540 |
Why?
|
| Oncologists | 3 | 2023 | 136 | 0.540 |
Why?
|
| Aneurysm | 2 | 2016 | 90 | 0.530 |
Why?
|
| Patient Satisfaction | 2 | 2015 | 917 | 0.520 |
Why?
|
| Professional-Patient Relations | 1 | 2016 | 114 | 0.520 |
Why?
|
| Anatomic Landmarks | 1 | 2016 | 51 | 0.520 |
Why?
|
| Electroencephalography | 3 | 2020 | 991 | 0.520 |
Why?
|
| Patient Compliance | 4 | 2020 | 676 | 0.510 |
Why?
|
| Carotid Artery, Internal | 1 | 2016 | 81 | 0.510 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2015 | 12 | 0.510 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 2399 | 0.500 |
Why?
|
| Cavernous Sinus | 1 | 2015 | 36 | 0.500 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2019 | 259 | 0.500 |
Why?
|
| Imatinib Mesylate | 2 | 2019 | 1691 | 0.500 |
Why?
|
| Quality of Life | 9 | 2023 | 4761 | 0.500 |
Why?
|
| Patient Navigation | 1 | 2015 | 33 | 0.490 |
Why?
|
| Immunotherapy | 4 | 2018 | 3557 | 0.490 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1379 | 0.480 |
Why?
|
| Continuity of Patient Care | 2 | 2014 | 206 | 0.480 |
Why?
|
| Patient Readmission | 1 | 2019 | 572 | 0.480 |
Why?
|
| Patient Protection and Affordable Care Act | 4 | 2023 | 107 | 0.470 |
Why?
|
| Craniopharyngioma | 2 | 2014 | 56 | 0.470 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2019 | 4961 | 0.470 |
Why?
|
| Age Factors | 14 | 2024 | 5457 | 0.470 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 477 | 0.470 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2013 | 2271 | 0.470 |
Why?
|
| Carotid Artery Diseases | 1 | 2016 | 176 | 0.470 |
Why?
|
| Central Nervous System Cysts | 1 | 2014 | 16 | 0.470 |
Why?
|
| Microsurgery | 3 | 2012 | 235 | 0.470 |
Why?
|
| Anterior Temporal Lobectomy | 3 | 2012 | 34 | 0.460 |
Why?
|
| Patient Discharge | 1 | 2019 | 698 | 0.460 |
Why?
|
| Radiotherapy | 4 | 2017 | 1857 | 0.460 |
Why?
|
| Evidence-Based Medicine | 4 | 2017 | 1034 | 0.450 |
Why?
|
| Poverty | 3 | 2023 | 486 | 0.450 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 247 | 0.450 |
Why?
|
| National Health Programs | 2 | 2010 | 40 | 0.440 |
Why?
|
| Lung Diseases | 1 | 2019 | 755 | 0.440 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2019 | 1838 | 0.440 |
Why?
|
| Epidemics | 1 | 2014 | 66 | 0.440 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2024 | 209 | 0.440 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2024 | 1903 | 0.430 |
Why?
|
| Mammaplasty | 2 | 2020 | 714 | 0.430 |
Why?
|
| Ambulatory Care | 4 | 2008 | 591 | 0.430 |
Why?
|
| Retrospective Studies | 34 | 2023 | 39890 | 0.430 |
Why?
|
| Hospitalization | 8 | 2019 | 2167 | 0.420 |
Why?
|
| Robotic Surgical Procedures | 2 | 2017 | 533 | 0.420 |
Why?
|
| Employment | 2 | 2024 | 121 | 0.420 |
Why?
|
| Economics, Medical | 2 | 2022 | 14 | 0.420 |
Why?
|
| Likelihood Functions | 1 | 2013 | 241 | 0.410 |
Why?
|
| Terminal Care | 2 | 2015 | 467 | 0.410 |
Why?
|
| Treatment Outcome | 27 | 2018 | 33737 | 0.410 |
Why?
|
| Cultural Characteristics | 1 | 2012 | 66 | 0.410 |
Why?
|
| Soil | 3 | 2022 | 59 | 0.410 |
Why?
|
| Patents as Topic | 1 | 2012 | 27 | 0.410 |
Why?
|
| Cystectomy | 1 | 2016 | 635 | 0.400 |
Why?
|
| Incidence | 12 | 2022 | 5824 | 0.400 |
Why?
|
| Cohort Studies | 17 | 2020 | 9470 | 0.400 |
Why?
|
| Breast | 3 | 2024 | 1369 | 0.390 |
Why?
|
| Pituitary Neoplasms | 1 | 2014 | 216 | 0.390 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2012 | 108 | 0.390 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 318 | 0.390 |
Why?
|
| Decision Making | 5 | 2023 | 1252 | 0.380 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2011 | 31 | 0.380 |
Why?
|
| Hospice Care | 1 | 2012 | 163 | 0.370 |
Why?
|
| Health Services for the Aged | 2 | 2012 | 50 | 0.370 |
Why?
|
| Octreotide | 3 | 2016 | 131 | 0.350 |
Why?
|
| Regression Analysis | 6 | 2017 | 1571 | 0.350 |
Why?
|
| Smokers | 2 | 2022 | 154 | 0.350 |
Why?
|
| Brachytherapy | 4 | 2020 | 1005 | 0.340 |
Why?
|
| Cross-Sectional Studies | 8 | 2023 | 4492 | 0.340 |
Why?
|
| Parenting | 1 | 2013 | 353 | 0.340 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 661 | 0.340 |
Why?
|
| Surveys and Questionnaires | 8 | 2022 | 5923 | 0.330 |
Why?
|
| Camptothecin | 1 | 2012 | 540 | 0.330 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 704 | 0.330 |
Why?
|
| Time Factors | 11 | 2019 | 13006 | 0.330 |
Why?
|
| Radiology | 1 | 2014 | 426 | 0.320 |
Why?
|
| Cognition Disorders | 1 | 2014 | 762 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 4481 | 0.320 |
Why?
|
| Yoga | 2 | 2022 | 88 | 0.320 |
Why?
|
| Age Distribution | 4 | 2019 | 727 | 0.320 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2023 | 7895 | 0.310 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2011 | 340 | 0.310 |
Why?
|
| Proportional Hazards Models | 8 | 2023 | 5101 | 0.310 |
Why?
|
| Forecasting | 2 | 2022 | 702 | 0.300 |
Why?
|
| Cancer Vaccines | 1 | 2014 | 754 | 0.300 |
Why?
|
| Young Adult | 16 | 2024 | 22251 | 0.300 |
Why?
|
| Physicians, Family | 1 | 2007 | 55 | 0.290 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2007 | 47 | 0.290 |
Why?
|
| Aging | 2 | 2018 | 1534 | 0.280 |
Why?
|
| Colonic Neoplasms | 3 | 2018 | 1435 | 0.280 |
Why?
|
| Medicaid | 2 | 2023 | 306 | 0.280 |
Why?
|
| Registries | 6 | 2018 | 2211 | 0.270 |
Why?
|
| Adolescent | 17 | 2024 | 32767 | 0.270 |
Why?
|
| Mental Disorders | 1 | 2014 | 882 | 0.270 |
Why?
|
| Melanoma | 1 | 2023 | 5595 | 0.270 |
Why?
|
| Socioeconomic Factors | 6 | 2015 | 1267 | 0.270 |
Why?
|
| Health Surveys | 4 | 2015 | 400 | 0.260 |
Why?
|
| Palliative Care | 2 | 2021 | 2178 | 0.260 |
Why?
|
| Longitudinal Studies | 7 | 2017 | 2057 | 0.260 |
Why?
|
| Neoplasm Staging | 14 | 2020 | 14012 | 0.260 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2016 | 841 | 0.260 |
Why?
|
| Health Resources | 2 | 2009 | 171 | 0.260 |
Why?
|
| Sickness Impact Profile | 1 | 2006 | 138 | 0.260 |
Why?
|
| Emigrants and Immigrants | 1 | 2008 | 159 | 0.260 |
Why?
|
| Family | 1 | 2010 | 783 | 0.250 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2007 | 117 | 0.250 |
Why?
|
| Formularies as Topic | 1 | 2004 | 3 | 0.250 |
Why?
|
| Risk Factors | 18 | 2024 | 17888 | 0.240 |
Why?
|
| Knowledge | 1 | 2004 | 48 | 0.240 |
Why?
|
| Influenza Vaccines | 1 | 2010 | 498 | 0.240 |
Why?
|
| Prostate-Specific Antigen | 4 | 2017 | 1029 | 0.240 |
Why?
|
| Case-Control Studies | 7 | 2021 | 6224 | 0.230 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 267 | 0.230 |
Why?
|
| Urinary Incontinence | 2 | 2013 | 148 | 0.230 |
Why?
|
| Observational Studies as Topic | 2 | 2015 | 144 | 0.230 |
Why?
|
| Private Sector | 2 | 2021 | 31 | 0.230 |
Why?
|
| Work | 1 | 2004 | 25 | 0.230 |
Why?
|
| Counseling | 4 | 2023 | 381 | 0.230 |
Why?
|
| Checklist | 2 | 2015 | 125 | 0.220 |
Why?
|
| Radiotherapy, Intensity-Modulated | 5 | 2020 | 2178 | 0.220 |
Why?
|
| Obesity | 1 | 2016 | 2904 | 0.220 |
Why?
|
| Health Care Surveys | 5 | 2011 | 418 | 0.220 |
Why?
|
| Efficiency | 1 | 2004 | 93 | 0.220 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2010 | 1067 | 0.220 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 2431 | 0.220 |
Why?
|
| Long-Term Care | 1 | 2003 | 85 | 0.220 |
Why?
|
| Peritoneal Dialysis | 1 | 2005 | 140 | 0.220 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 1432 | 0.220 |
Why?
|
| Mindfulness | 1 | 2023 | 56 | 0.210 |
Why?
|
| Patient Care | 1 | 2004 | 148 | 0.210 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2003 | 92 | 0.210 |
Why?
|
| Risk | 4 | 2021 | 1939 | 0.210 |
Why?
|
| Influenza, Human | 1 | 2010 | 765 | 0.210 |
Why?
|
| Nursing Homes | 1 | 2003 | 100 | 0.210 |
Why?
|
| Models, Theoretical | 2 | 2019 | 799 | 0.210 |
Why?
|
| Colonic Diseases, Functional | 1 | 2002 | 19 | 0.210 |
Why?
|
| Odds Ratio | 8 | 2018 | 2311 | 0.210 |
Why?
|
| Vomiting | 2 | 2010 | 361 | 0.210 |
Why?
|
| Kidney Failure, Chronic | 2 | 2013 | 953 | 0.200 |
Why?
|
| Colonoscopy | 1 | 2006 | 522 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 3409 | 0.200 |
Why?
|
| Soil Pollutants | 1 | 2022 | 13 | 0.200 |
Why?
|
| Survival Rate | 9 | 2019 | 12541 | 0.200 |
Why?
|
| Disease | 1 | 2004 | 165 | 0.200 |
Why?
|
| Drug Utilization | 1 | 2003 | 188 | 0.200 |
Why?
|
| Sarcoma | 1 | 2012 | 1839 | 0.190 |
Why?
|
| Ambulatory Care Facilities | 1 | 2024 | 293 | 0.190 |
Why?
|
| Decision Support Techniques | 1 | 2007 | 602 | 0.190 |
Why?
|
| Drug Packaging | 1 | 2021 | 13 | 0.190 |
Why?
|
| Deductibles and Coinsurance | 1 | 2021 | 10 | 0.190 |
Why?
|
| Minority Groups | 1 | 2023 | 328 | 0.190 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2021 | 7044 | 0.190 |
Why?
|
| Radiation Oncologists | 1 | 2021 | 32 | 0.180 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 2224 | 0.180 |
Why?
|
| Survivors | 3 | 2023 | 1021 | 0.180 |
Why?
|
| Papillomaviridae | 2 | 2021 | 636 | 0.180 |
Why?
|
| Antidepressive Agents | 1 | 2003 | 335 | 0.180 |
Why?
|
| Nitrogen Fixation | 1 | 2019 | 6 | 0.180 |
Why?
|
| Halogenation | 1 | 2019 | 14 | 0.170 |
Why?
|
| Administration, Intravenous | 1 | 2021 | 248 | 0.170 |
Why?
|
| Medically Uninsured | 1 | 2020 | 106 | 0.170 |
Why?
|
| Pharmacists | 1 | 2020 | 97 | 0.170 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 15218 | 0.170 |
Why?
|
| Time | 1 | 2020 | 183 | 0.170 |
Why?
|
| Public Health | 1 | 2022 | 296 | 0.170 |
Why?
|
| Health Maintenance Organizations | 2 | 2013 | 27 | 0.170 |
Why?
|
| Risk Assessment | 7 | 2019 | 6764 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 172 | 0.170 |
Why?
|
| Cost Savings | 3 | 2019 | 123 | 0.170 |
Why?
|
| Depression | 2 | 2023 | 1730 | 0.170 |
Why?
|
| Radiation Oncology | 2 | 2015 | 558 | 0.160 |
Why?
|
| Electrodes, Implanted | 1 | 2020 | 185 | 0.160 |
Why?
|
| Hospitals, Low-Volume | 1 | 2019 | 51 | 0.160 |
Why?
|
| Bone Screws | 2 | 2010 | 86 | 0.160 |
Why?
|
| Health Personnel | 1 | 2004 | 652 | 0.160 |
Why?
|
| Environmental Pollutants | 1 | 2019 | 86 | 0.160 |
Why?
|
| Depressive Disorder | 1 | 2003 | 565 | 0.160 |
Why?
|
| Health Services Needs and Demand | 2 | 2019 | 247 | 0.160 |
Why?
|
| Income | 3 | 2024 | 235 | 0.160 |
Why?
|
| Hospitals, High-Volume | 1 | 2019 | 76 | 0.160 |
Why?
|
| Asthma | 1 | 2007 | 895 | 0.160 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2019 | 600 | 0.160 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2011 | 1229 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 861 | 0.160 |
Why?
|
| Chromatography, Liquid | 1 | 2019 | 354 | 0.160 |
Why?
|
| Renal Dialysis | 1 | 2005 | 917 | 0.150 |
Why?
|
| Developing Countries | 2 | 2012 | 349 | 0.150 |
Why?
|
| Motivation | 4 | 2023 | 516 | 0.150 |
Why?
|
| Cohort Effect | 1 | 2017 | 9 | 0.150 |
Why?
|
| Health Insurance Exchanges | 1 | 2017 | 7 | 0.150 |
Why?
|
| Multivariate Analysis | 8 | 2018 | 4328 | 0.150 |
Why?
|
| Bayes Theorem | 3 | 2009 | 1060 | 0.150 |
Why?
|
| Patient Care Bundles | 1 | 2018 | 30 | 0.150 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2023 | 218 | 0.150 |
Why?
|
| Insurance Benefits | 2 | 2018 | 6 | 0.150 |
Why?
|
| State Government | 1 | 2017 | 33 | 0.150 |
Why?
|
| Cost Sharing | 1 | 2017 | 7 | 0.140 |
Why?
|
| Pyrimidines | 3 | 2019 | 3669 | 0.140 |
Why?
|
| Hepatitis B virus | 1 | 2019 | 225 | 0.140 |
Why?
|
| Carcinoma, Ductal | 1 | 2018 | 144 | 0.140 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 722 | 0.140 |
Why?
|
| Markov Chains | 2 | 2015 | 185 | 0.140 |
Why?
|
| Indazoles | 1 | 2019 | 310 | 0.140 |
Why?
|
| Child, Preschool | 3 | 2020 | 17061 | 0.140 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 42 | 0.140 |
Why?
|
| Child | 5 | 2024 | 30559 | 0.140 |
Why?
|
| Comorbidity | 4 | 2017 | 2394 | 0.140 |
Why?
|
| Digital Rectal Examination | 1 | 2016 | 14 | 0.140 |
Why?
|
| California | 1 | 2017 | 212 | 0.140 |
Why?
|
| Precision Medicine | 2 | 2022 | 1207 | 0.140 |
Why?
|
| Sex Factors | 3 | 2015 | 2184 | 0.140 |
Why?
|
| Cerebral Angiography | 2 | 2015 | 148 | 0.140 |
Why?
|
| Patient Preference | 1 | 2019 | 229 | 0.140 |
Why?
|
| Cost Control | 2 | 2008 | 45 | 0.140 |
Why?
|
| Prognosis | 9 | 2019 | 22505 | 0.140 |
Why?
|
| Analysis of Variance | 2 | 2010 | 2315 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2023 | 2650 | 0.130 |
Why?
|
| Mortality | 1 | 2018 | 347 | 0.130 |
Why?
|
| Computer Simulation | 3 | 2024 | 1570 | 0.130 |
Why?
|
| Hepatitis B | 1 | 2019 | 275 | 0.130 |
Why?
|
| Gastrectomy | 1 | 2019 | 476 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 271 | 0.130 |
Why?
|
| Attitude | 1 | 2016 | 162 | 0.130 |
Why?
|
| Prostate | 2 | 2018 | 1089 | 0.130 |
Why?
|
| Models, Econometric | 1 | 2015 | 14 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 4895 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 2 | 2021 | 1388 | 0.130 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 368 | 0.130 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2015 | 77 | 0.130 |
Why?
|
| Muscle, Smooth | 1 | 2016 | 251 | 0.130 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 166 | 0.130 |
Why?
|
| Radiation Injuries | 3 | 2018 | 1471 | 0.120 |
Why?
|
| Nausea | 1 | 2007 | 539 | 0.120 |
Why?
|
| Urology | 1 | 2017 | 140 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2019 | 647 | 0.120 |
Why?
|
| Self-Examination | 1 | 2014 | 12 | 0.120 |
Why?
|
| Hospital Mortality | 2 | 2019 | 1234 | 0.120 |
Why?
|
| Health Promotion | 1 | 2019 | 510 | 0.120 |
Why?
|
| Facial Nerve Injuries | 1 | 2014 | 10 | 0.120 |
Why?
|
| Program Evaluation | 2 | 2022 | 603 | 0.120 |
Why?
|
| Cerebellopontine Angle | 1 | 2014 | 12 | 0.120 |
Why?
|
| Mastoid | 1 | 2014 | 31 | 0.120 |
Why?
|
| Health Services | 1 | 2015 | 100 | 0.120 |
Why?
|
| Insurance Claim Reporting | 2 | 2017 | 14 | 0.120 |
Why?
|
| Patients | 1 | 2016 | 246 | 0.120 |
Why?
|
| Facial Paralysis | 1 | 2014 | 57 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 4 | 2016 | 4048 | 0.120 |
Why?
|
| Cesarean Section, Repeat | 1 | 2014 | 7 | 0.120 |
Why?
|
| Electric Impedance | 1 | 2014 | 101 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2023 | 4000 | 0.120 |
Why?
|
| Genital Neoplasms, Female | 1 | 2021 | 794 | 0.120 |
Why?
|
| Preferred Provider Organizations | 1 | 2013 | 4 | 0.120 |
Why?
|
| Policy Making | 2 | 2018 | 76 | 0.120 |
Why?
|
| Epirubicin | 2 | 2017 | 159 | 0.120 |
Why?
|
| Pelvis | 1 | 2016 | 381 | 0.110 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 300 | 0.110 |
Why?
|
| Child Rearing | 1 | 2013 | 30 | 0.110 |
Why?
|
| Trial of Labor | 1 | 2014 | 22 | 0.110 |
Why?
|
| Surgeons | 1 | 2020 | 491 | 0.110 |
Why?
|
| Vaginal Birth after Cesarean | 1 | 2014 | 24 | 0.110 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 372 | 0.110 |
Why?
|
| Proton Therapy | 3 | 2020 | 1637 | 0.110 |
Why?
|
| Dementia | 1 | 2019 | 473 | 0.110 |
Why?
|
| Drug Industry | 1 | 2013 | 88 | 0.110 |
Why?
|
| Virginia | 1 | 2013 | 23 | 0.110 |
Why?
|
| Nomograms | 2 | 2014 | 312 | 0.110 |
Why?
|
| American Cancer Society | 3 | 2020 | 35 | 0.110 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2019 | 1144 | 0.110 |
Why?
|
| Prevalence | 2 | 2019 | 3404 | 0.110 |
Why?
|
| Iatrogenic Disease | 1 | 2014 | 195 | 0.110 |
Why?
|
| Legislation as Topic | 1 | 2013 | 5 | 0.110 |
Why?
|
| Alcoholism | 1 | 2016 | 332 | 0.110 |
Why?
|
| Lymph Node Excision | 2 | 2024 | 2062 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2020 | 801 | 0.110 |
Why?
|
| Diarrhea | 1 | 2017 | 716 | 0.110 |
Why?
|
| Research Support as Topic | 1 | 2013 | 120 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2019 | 724 | 0.110 |
Why?
|
| Somatosensory Disorders | 1 | 2012 | 5 | 0.110 |
Why?
|
| Chemoprevention | 1 | 2014 | 251 | 0.110 |
Why?
|
| Meningioma | 2 | 2014 | 308 | 0.110 |
Why?
|
| Workload | 1 | 2014 | 194 | 0.110 |
Why?
|
| Waiting Lists | 1 | 2015 | 267 | 0.110 |
Why?
|
| Perception | 1 | 2015 | 349 | 0.110 |
Why?
|
| Remission Induction | 1 | 2019 | 3656 | 0.100 |
Why?
|
| Operative Time | 1 | 2014 | 255 | 0.100 |
Why?
|
| Diffusion of Innovation | 2 | 2014 | 141 | 0.100 |
Why?
|
| Time-to-Treatment | 1 | 2015 | 307 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 16689 | 0.100 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2012 | 75 | 0.100 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2012 | 7 | 0.100 |
Why?
|
| Microvascular Decompression Surgery | 1 | 2012 | 11 | 0.100 |
Why?
|
| Drug Utilization Review | 2 | 2019 | 37 | 0.100 |
Why?
|
| Nerve Net | 1 | 2015 | 272 | 0.100 |
Why?
|
| Goals | 2 | 2023 | 187 | 0.100 |
Why?
|
| Developed Countries | 1 | 2012 | 46 | 0.100 |
Why?
|
| Social Class | 2 | 2019 | 324 | 0.100 |
Why?
|
| Vertebral Artery | 2 | 2014 | 33 | 0.100 |
Why?
|
| Frail Elderly | 1 | 2012 | 98 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 880 | 0.100 |
Why?
|
| Hematologic Neoplasms | 2 | 2018 | 1956 | 0.100 |
Why?
|
| Government Programs | 1 | 2011 | 16 | 0.100 |
Why?
|
| Pandemics | 1 | 2021 | 1610 | 0.100 |
Why?
|
| Hormone Replacement Therapy | 1 | 2014 | 214 | 0.100 |
Why?
|
| Glioma | 1 | 2022 | 1978 | 0.100 |
Why?
|
| Fees and Charges | 1 | 2011 | 13 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 1235 | 0.090 |
Why?
|
| Texas | 6 | 2019 | 6449 | 0.090 |
Why?
|
| Rural Health Services | 2 | 2021 | 37 | 0.090 |
Why?
|
| Drug Prescriptions | 2 | 2004 | 311 | 0.090 |
Why?
|
| Fatigue | 1 | 2017 | 1275 | 0.090 |
Why?
|
| Trastuzumab | 1 | 2014 | 743 | 0.090 |
Why?
|
| Physician Incentive Plans | 1 | 2010 | 17 | 0.090 |
Why?
|
| Infant | 2 | 2018 | 13999 | 0.090 |
Why?
|
| Serotonin Antagonists | 1 | 2010 | 50 | 0.090 |
Why?
|
| Androgens | 1 | 2014 | 506 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2018 | 10400 | 0.090 |
Why?
|
| Spondylosis | 1 | 2010 | 5 | 0.090 |
Why?
|
| Metformin | 1 | 2014 | 393 | 0.090 |
Why?
|
| Quinuclidines | 1 | 2010 | 46 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 1255 | 0.090 |
Why?
|
| Isoquinolines | 1 | 2010 | 125 | 0.090 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 1145 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 599 | 0.090 |
Why?
|
| Hypogonadism | 1 | 2014 | 278 | 0.090 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 1024 | 0.090 |
Why?
|
| Thromboembolism | 1 | 2011 | 150 | 0.090 |
Why?
|
| Survival Analysis | 4 | 2018 | 9292 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 4831 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2018 | 2033 | 0.080 |
Why?
|
| Fluorouracil | 2 | 2017 | 1990 | 0.080 |
Why?
|
| Developmental Disabilities | 1 | 2014 | 697 | 0.080 |
Why?
|
| S100 Proteins | 1 | 2010 | 186 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2019 | 1933 | 0.080 |
Why?
|
| Breast Neoplasms, Male | 1 | 2011 | 232 | 0.080 |
Why?
|
| Hemangiopericytoma | 1 | 2009 | 59 | 0.080 |
Why?
|
| Biopsy | 2 | 2018 | 3484 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2011 | 666 | 0.080 |
Why?
|
| Dura Mater | 1 | 2009 | 85 | 0.080 |
Why?
|
| Economics, Pharmaceutical | 1 | 2009 | 16 | 0.080 |
Why?
|
| Robotics | 1 | 2013 | 365 | 0.080 |
Why?
|
| Information Systems | 1 | 2009 | 53 | 0.080 |
Why?
|
| Fracture Fixation | 1 | 2008 | 34 | 0.080 |
Why?
|
| Testosterone | 1 | 2014 | 638 | 0.080 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2011 | 509 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 2 | 2015 | 483 | 0.080 |
Why?
|
| Budgets | 1 | 2008 | 24 | 0.080 |
Why?
|
| Thoracic Vertebrae | 1 | 2009 | 200 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 984 | 0.080 |
Why?
|
| Educational Status | 2 | 2007 | 392 | 0.080 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2009 | 155 | 0.080 |
Why?
|
| Psychometrics | 2 | 2022 | 973 | 0.080 |
Why?
|
| Prostheses and Implants | 1 | 2010 | 294 | 0.080 |
Why?
|
| Ki-67 Antigen | 1 | 2010 | 675 | 0.080 |
Why?
|
| Prosthesis Implantation | 1 | 2010 | 242 | 0.080 |
Why?
|
| Radiotherapy Dosage | 3 | 2011 | 4019 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2024 | 2828 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 4372 | 0.070 |
Why?
|
| Patient Selection | 3 | 2024 | 2025 | 0.070 |
Why?
|
| Disease Progression | 2 | 2018 | 6867 | 0.070 |
Why?
|
| Cervical Vertebrae | 1 | 2008 | 219 | 0.070 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2007 | 28 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2012 | 1275 | 0.070 |
Why?
|
| Orthopedic Procedures | 1 | 2008 | 145 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2016 | 6256 | 0.070 |
Why?
|
| Subdural Space | 1 | 2007 | 8 | 0.070 |
Why?
|
| Subdural Effusion | 1 | 2007 | 10 | 0.070 |
Why?
|
| Spine | 1 | 2008 | 312 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 9039 | 0.070 |
Why?
|
| Fluoxetine | 1 | 2007 | 46 | 0.070 |
Why?
|
| Citalopram | 1 | 2007 | 34 | 0.070 |
Why?
|
| Paroxetine | 1 | 2007 | 36 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 824 | 0.070 |
Why?
|
| Smoking | 3 | 2024 | 2555 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2013 | 761 | 0.070 |
Why?
|
| Global Health | 1 | 2012 | 692 | 0.070 |
Why?
|
| Sertraline | 1 | 2007 | 42 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 2331 | 0.070 |
Why?
|
| Cyclophosphamide | 2 | 2017 | 3245 | 0.070 |
Why?
|
| Quality Improvement | 1 | 2014 | 914 | 0.070 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2007 | 86 | 0.070 |
Why?
|
| Specialization | 1 | 2007 | 128 | 0.070 |
Why?
|
| Decision Trees | 2 | 2019 | 181 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2665 | 0.070 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2007 | 101 | 0.070 |
Why?
|
| Hypothyroidism | 1 | 2008 | 206 | 0.070 |
Why?
|
| Emigration and Immigration | 1 | 2006 | 97 | 0.070 |
Why?
|
| Eosinophils | 1 | 2007 | 166 | 0.060 |
Why?
|
| Medicine | 1 | 2007 | 136 | 0.060 |
Why?
|
| Neoplasm Grading | 3 | 2017 | 1823 | 0.060 |
Why?
|
| Intracranial Hypertension | 1 | 2007 | 126 | 0.060 |
Why?
|
| Algorithms | 2 | 2007 | 3891 | 0.060 |
Why?
|
| Methotrexate | 1 | 2009 | 1025 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2020 | 13414 | 0.060 |
Why?
|
| Data Collection | 1 | 2007 | 608 | 0.060 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 745 | 0.060 |
Why?
|
| Recurrence | 2 | 2010 | 4878 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2007 | 633 | 0.060 |
Why?
|
| Adaptation, Psychological | 2 | 2022 | 787 | 0.060 |
Why?
|
| Research Design | 3 | 2022 | 1569 | 0.060 |
Why?
|
| Cytokines | 1 | 2014 | 2825 | 0.060 |
Why?
|
| China | 1 | 2006 | 636 | 0.060 |
Why?
|
| Reimbursement Mechanisms | 2 | 2018 | 76 | 0.060 |
Why?
|
| Dalteparin | 1 | 2004 | 11 | 0.060 |
Why?
|
| Episode of Care | 1 | 2004 | 9 | 0.060 |
Why?
|
| Morbidity | 1 | 2005 | 400 | 0.060 |
Why?
|
| Carcinoma, Lobular | 1 | 2008 | 616 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2004 | 205 | 0.060 |
Why?
|
| Receptor, ErbB-2 | 1 | 2014 | 2651 | 0.060 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 10265 | 0.060 |
Why?
|
| North Carolina | 1 | 2003 | 82 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2013 | 1302 | 0.060 |
Why?
|
| Comparative Effectiveness Research | 2 | 2014 | 116 | 0.050 |
Why?
|
| Neutropenia | 1 | 2008 | 1006 | 0.050 |
Why?
|
| Facial Nerve | 2 | 2014 | 58 | 0.050 |
Why?
|
| Medical Records | 1 | 2004 | 442 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 5257 | 0.050 |
Why?
|
| Transplantation, Homologous | 2 | 2021 | 3046 | 0.050 |
Why?
|
| Cerebellum | 1 | 2007 | 470 | 0.050 |
Why?
|
| Hallucinations | 1 | 2003 | 34 | 0.050 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2003 | 62 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 1690 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 6177 | 0.050 |
Why?
|
| Reimbursement, Incentive | 1 | 2023 | 51 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2004 | 234 | 0.050 |
Why?
|
| Transplantation, Autologous | 3 | 2018 | 2067 | 0.050 |
Why?
|
| Cytarabine | 1 | 2009 | 2014 | 0.050 |
Why?
|
| Length of Stay | 3 | 2008 | 2007 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 1894 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2004 | 356 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2004 | 268 | 0.050 |
Why?
|
| Smartphone | 1 | 2022 | 48 | 0.050 |
Why?
|
| Smell | 1 | 2003 | 134 | 0.050 |
Why?
|
| Heparin | 1 | 2004 | 342 | 0.050 |
Why?
|
| Health Behavior | 1 | 2006 | 601 | 0.050 |
Why?
|
| Linear Models | 2 | 2015 | 1093 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2004 | 293 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2022 | 353 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2006 | 907 | 0.050 |
Why?
|
| Axilla | 1 | 2024 | 939 | 0.050 |
Why?
|
| Geography | 1 | 2021 | 140 | 0.050 |
Why?
|
| Smoking Prevention | 1 | 2022 | 144 | 0.050 |
Why?
|
| Professional Practice Location | 1 | 2020 | 15 | 0.050 |
Why?
|
| Geography, Medical | 1 | 2020 | 22 | 0.050 |
Why?
|
| Metagenomics | 1 | 2022 | 121 | 0.050 |
Why?
|
| Therapeutic Equivalency | 1 | 2010 | 49 | 0.050 |
Why?
|
| Urban Health Services | 1 | 2020 | 34 | 0.050 |
Why?
|
| Monte Carlo Method | 2 | 2014 | 706 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2014 | 749 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2004 | 379 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 5574 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2018 | 1933 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2010 | 153 | 0.040 |
Why?
|
| Heart Failure | 1 | 2013 | 2330 | 0.040 |
Why?
|
| Psychiatry | 1 | 2003 | 275 | 0.040 |
Why?
|
| Vaginal Smears | 1 | 2020 | 166 | 0.040 |
Why?
|
| Lymphoma | 1 | 2008 | 1519 | 0.040 |
Why?
|
| Fraud | 1 | 2019 | 18 | 0.040 |
Why?
|
| Physicians, Women | 1 | 2020 | 103 | 0.040 |
Why?
|
| Rural Population | 1 | 2021 | 292 | 0.040 |
Why?
|
| Minority Health | 1 | 2019 | 16 | 0.040 |
Why?
|
| Deprescriptions | 1 | 2019 | 25 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2010 | 347 | 0.040 |
Why?
|
| Pharmaceutical Services | 1 | 2019 | 36 | 0.040 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 89 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2010 | 352 | 0.040 |
Why?
|
| Intestine, Large | 1 | 2018 | 32 | 0.040 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 121 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2004 | 775 | 0.040 |
Why?
|
| Peptic Ulcer | 1 | 2019 | 161 | 0.040 |
Why?
|
| Muscle Stretching Exercises | 1 | 2017 | 14 | 0.040 |
Why?
|
| Lymphatic Metastasis | 3 | 2012 | 4963 | 0.040 |
Why?
|
| Government Regulation | 1 | 2018 | 58 | 0.040 |
Why?
|
| Papillomavirus Vaccines | 1 | 2020 | 197 | 0.040 |
Why?
|
| Chicago | 1 | 2017 | 40 | 0.040 |
Why?
|
| Actigraphy | 1 | 2017 | 54 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2019 | 572 | 0.040 |
Why?
|
| New York | 1 | 2017 | 103 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2016 | 67 | 0.030 |
Why?
|
| Medical Errors | 1 | 2019 | 210 | 0.030 |
Why?
|
| Problem Solving | 1 | 2016 | 89 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2003 | 831 | 0.030 |
Why?
|
| Antiemetics | 1 | 2007 | 122 | 0.030 |
Why?
|
| Age of Onset | 1 | 2018 | 853 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2008 | 2328 | 0.030 |
Why?
|
| Caregivers | 1 | 2022 | 752 | 0.030 |
Why?
|
| Population Groups | 1 | 2015 | 39 | 0.030 |
Why?
|
| Image-Guided Biopsy | 1 | 2018 | 336 | 0.030 |
Why?
|
| Cholesterol | 1 | 2018 | 659 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2019 | 642 | 0.030 |
Why?
|
| Review Literature as Topic | 1 | 2015 | 84 | 0.030 |
Why?
|
| Magnetoencephalography | 1 | 2015 | 44 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 789 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2015 | 129 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2018 | 593 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 1312 | 0.030 |
Why?
|
| Bias | 1 | 2015 | 216 | 0.030 |
Why?
|
| Publication Bias | 1 | 2014 | 37 | 0.030 |
Why?
|
| Vipoma | 1 | 2014 | 18 | 0.030 |
Why?
|
| Professional Practice | 1 | 2014 | 80 | 0.030 |
Why?
|
| Cross Infection | 1 | 2019 | 550 | 0.030 |
Why?
|
| Sleep | 1 | 2017 | 442 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 678 | 0.030 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 1386 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2014 | 233 | 0.030 |
Why?
|
| Electromyography | 1 | 2014 | 230 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 1015 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2024 | 3077 | 0.030 |
Why?
|
| Indocyanine Green | 1 | 2014 | 125 | 0.030 |
Why?
|
| Maternal Mortality | 1 | 2014 | 81 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 3844 | 0.030 |
Why?
|
| Optical Imaging | 1 | 2014 | 158 | 0.030 |
Why?
|
| Life Style | 1 | 2016 | 618 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 600 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2014 | 231 | 0.030 |
Why?
|
| Self Care | 1 | 2014 | 246 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2014 | 178 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2018 | 1568 | 0.030 |
Why?
|
| Petrous Bone | 1 | 2012 | 10 | 0.030 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2012 | 45 | 0.030 |
Why?
|
| Facial Pain | 1 | 2012 | 20 | 0.030 |
Why?
|
| Rib Fractures | 1 | 2012 | 38 | 0.030 |
Why?
|
| Hemifacial Spasm | 1 | 2012 | 22 | 0.020 |
Why?
|
| Fee-for-Service Plans | 1 | 2012 | 43 | 0.020 |
Why?
|
| Fat Necrosis | 1 | 2012 | 60 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 999 | 0.020 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2014 | 182 | 0.020 |
Why?
|
| Trigeminal Neuralgia | 1 | 2012 | 42 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2015 | 624 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 1097 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2012 | 274 | 0.020 |
Why?
|
| Surgical Instruments | 1 | 2012 | 141 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2014 | 360 | 0.020 |
Why?
|
| Organ Sparing Treatments | 1 | 2013 | 283 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 4960 | 0.020 |
Why?
|
| Propensity Score | 1 | 2014 | 772 | 0.020 |
Why?
|
| Erectile Dysfunction | 1 | 2013 | 239 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2017 | 3145 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2014 | 684 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2012 | 339 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2010 | 322 | 0.020 |
Why?
|
| Exercise | 1 | 2016 | 1184 | 0.020 |
Why?
|
| Diet | 1 | 2016 | 1477 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2014 | 564 | 0.020 |
Why?
|
| Patient Safety | 1 | 2014 | 613 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 3530 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 5056 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2012 | 1042 | 0.020 |
Why?
|
| Foramen Magnum | 1 | 2007 | 7 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 2008 | 138 | 0.020 |
Why?
|
| Spinal Canal | 1 | 2007 | 15 | 0.020 |
Why?
|
| Cervical Atlas | 1 | 2007 | 21 | 0.020 |
Why?
|
| Subarachnoid Space | 1 | 2007 | 39 | 0.020 |
Why?
|
| Fourth Ventricle | 1 | 2007 | 49 | 0.020 |
Why?
|
| Medulla Oblongata | 1 | 2007 | 47 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 2810 | 0.020 |
Why?
|
| Critical Pathways | 1 | 2008 | 160 | 0.020 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2007 | 89 | 0.020 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 10708 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2007 | 323 | 0.020 |
Why?
|
| Stomatitis | 1 | 2007 | 193 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2014 | 2123 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 2170 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2007 | 500 | 0.020 |
Why?
|
| Fever | 1 | 2008 | 521 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2007 | 822 | 0.010 |
Why?
|
| Hydrocephalus | 1 | 2007 | 259 | 0.010 |
Why?
|
| Radiography | 1 | 2008 | 1986 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2017 | 5231 | 0.010 |
Why?
|
| Pain | 1 | 2012 | 1694 | 0.010 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2004 | 62 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2007 | 1430 | 0.010 |
Why?
|
| Amygdala | 1 | 2003 | 110 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2007 | 2580 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 7655 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 2003 | 191 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2007 | 619 | 0.010 |
Why?
|
| Benzamides | 1 | 2007 | 1879 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 2457 | 0.010 |
Why?
|
| Pregnancy | 1 | 2014 | 8130 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2014 | 8699 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 4795 | 0.010 |
Why?
|
| Brain Diseases | 1 | 2003 | 412 | 0.010 |
Why?
|
| Inpatients | 1 | 2004 | 683 | 0.010 |
Why?
|
| Piperazines | 1 | 2007 | 2145 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 4958 | 0.000 |
Why?
|